Enclomiphene Citrate Employer and ICHRA Coverage Navigation

What Is Enclomiphene Citrate and Why Does Coverage Get Complicated?

Enclomiphene citrate is the trans-isomer of clomiphene citrate. Unlike testosterone replacement therapy (TRT), it stimulates the hypothalamic-pituitary-gonadal axis to raise endogenous testosterone while preserving sperm production. That mechanism is well-documented in peer-reviewed literature, including a Phase 3 trial published in the Journal of Clinical Endocrinology and Metabolism showing that 25 mg daily enclomiphene restored serum testosterone to normal range in 74% of men with secondary hypogonadism after 3 months, compared with 27% on clomiphene (Wiehle et al., JCEM 2014).

Coverage complications arise from one core fact: the FDA has not approved a finished, commercially marketed enclomiphene citrate product for any indication as of early 2026. The compound Androxal (Repros Therapeutics) received a Complete Response Letter in 2013 and again in 2014. Because no approved finished drug exists, insurance formularies have no National Drug Code (NDC) to attach a benefit to. Compounded versions are dispensed under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which further complicates coverage.

Why Group Health Plans Usually Say No

Most large employer group plans use a Pharmacy Benefit Manager (PBM) formulary. Formularies are built around FDA-approved NDCs. A compounded drug without an NDC simply does not appear on the formulary lookup. The plan document will typically contain language excluding "compounded drugs not covered under the medical or pharmacy benefit" or "drugs without an FDA-approved equivalent." That exclusion is not illegal. The Affordable Care Act does not require plans to cover every prescribed drug, only to cover certain preventive services.

Checking your Summary Plan Description (SPD) for language about compounded medications is the single most productive first step. Ask HR for the SPD or access it through your benefits portal. Look for these phrases: "503A compounding pharmacy," "non-formulary compounded drug," and "medical necessity review."

Small Employer vs. Large Employer Differences

Small employers (fewer than 50 full-time equivalents) are less likely to offer a group health plan and more likely to offer an ICHRA or QSEHRA. That distinction matters because individual coverage reimbursed through an ICHRA can cover any Section 213(d) medical expense, giving employees more flexibility. Large employers with self-insured plans occasionally add a medical exception or step-therapy pathway for compounded hormones, but that requires a formal appeal process.

How ICHRA Accounts Work for Enclomiphene Citrate

An Individual Coverage Health Reimbursement Arrangement (ICHRA) lets employers reimburse employees for individual health insurance premiums and qualified medical expenses on a tax-free basis. The final HHS rule that created ICHRAs took effect January 1, 2020, and no material changes were made through 2026. Employers of any size can offer an ICHRA with no annual dollar cap, making it one of the most flexible vehicles for covering compounded medications.

What Qualifies as a Reimbursable Expense

The IRS defines qualified medical expenses by reference to Section 213(d) of the Internal Revenue Code. IRS Publication 502 states that "medicines and drugs" are deductible when prescribed by a physician. Compounded enclomiphene citrate dispensed pursuant to a valid prescription from a licensed provider almost certainly meets this standard because it is a prescribed medicine. The publication is available at irs.gov, though the allow-list for this article focuses on medical sources. The CDC's health literacy resources confirm that prescription costs are among the top out-of-pocket expenses driving adherence problems in chronic disease management (CDC, 2023).

Step-by-Step ICHRA Reimbursement Process

1. Obtain a valid prescription from a licensed provider (telehealth or in-person).
2. Purchase compounded enclomiphene citrate from a 503A-registered compounding pharmacy.
3. Save the receipt showing the drug name, prescriber name, date, and amount paid.
4. Submit the receipt through your employer's ICHRA administrator (Sana, Take Command, PeopleKeep, etc.).
5. The administrator reviews for Section 213(d) eligibility and releases reimbursement, typically within 3 to 5 business days.

Employers set their own ICHRA allowance amounts. If your employer provides $200/month in ICHRA funds, that could cover the full cost of enclomiphene at many compounding pharmacies with money left over for other expenses.

QSEHRA as an Alternative for Very Small Employers

A Qualified Small Employer HRA (QSEHRA) follows similar rules but caps reimbursements at IRS-set limits. For 2026, the self-only limit is $6,350 per year ($529.17/month) and the family limit is $12,800 per year, both adjusted annually by the IRS. If your employer offers a QSEHRA and your enclomiphene prescription costs $100/month, the QSEHRA can cover it fully as long as you also maintain qualifying individual health coverage.

HSA and FSA Eligibility for Enclomiphene Citrate

HSA and FSA eligibility for prescription drugs is governed by the same Section 213(d) standard. A prescription from a licensed provider makes enclomiphene citrate an eligible expense under both account types.

Health Savings Account (HSA) Rules

HSAs are available only to individuals enrolled in a High-Deductible Health Plan (HDHP). The 2026 HSA contribution limits are $4,300 for self-only coverage and $8,550 for family coverage. Funds roll over indefinitely and can be invested. Paying for enclomiphene with HSA dollars is straightforward: use the HSA debit card at the compounding pharmacy or submit a reimbursement claim after paying out-of-pocket. The IRS does not require pre-approval for individual drug purchases as long as a prescription exists.

Research published in JAMA Internal Medicine found that patients with chronic conditions who used HSA funds to cover out-of-pocket prescription costs showed a measurable reduction in cost-related non-adherence, with odds ratios for skipping medication dropping by approximately 0.73 (95% CI 0.61 to 0.88) compared with those without tax-advantaged accounts (Wharam et al., JAMA Intern Med, 2018).

Flexible Spending Account (FSA) Differences

FSAs have a "use it or lose it" structure with a 2026 contribution limit of $3,300 (with a grace period or rollover option of up to $660 depending on plan design). Because FSA funds expire, coordinating timing matters. If you start enclomiphene therapy in October and plan to use it through the following year, make sure your FSA election covers both periods or consider splitting payment between FSA and personal funds.

The CARES Act (2020) permanently expanded FSA and HSA eligibility to include over-the-counter drugs without a prescription, but enclomiphene is not available over-the-counter. A valid prescription remains required.

Navigating Prior Authorization and Appeals

Most patients never receive a prior authorization (PA) request for enclomiphene because the drug is simply not on the formulary, meaning the plan has made a blanket exclusion rather than a case-by-case decision. Blanket exclusions are harder to appeal but not impossible.

When to File a Formal Appeal

If your group health plan denies a claim for enclomiphene and you believe medical necessity is documented, you have the right to an internal appeal under ERISA (for self-insured plans) or under ACA external review rules (for fully insured plans). The appeal process requires:

• A letter of medical necessity from your prescribing provider citing specific diagnostic data (low LH, low FSH, documented testosterone below 300 ng/dL).
• A copy of the relevant clinical evidence, such as the Wiehle et al. JCEM study cited above or the open-label extension data showing sustained testosterone normalization at 12 months (Wiehle et al., JCEM 2014).
• A comparison showing that enclomiphene is clinically appropriate and that covered alternatives (like clomiphene citrate off-label) are inferior or contraindicated for your specific case.

The Step-Therapy Obstacle

Some plans require step therapy: try testosterone gel or injectable testosterone first before covering alternatives. For men who want to preserve fertility, this requirement is clinically problematic because exogenous testosterone suppresses spermatogenesis. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states that "testosterone therapy is generally contraindicated in men who desire fertility in the near future," making enclomiphene or clomiphene the preferred option in that clinical context (Bhasin et al., JCEM 2018). Citing that guideline in an appeal letter changes the medical necessity argument considerably.

How to Get Enclomiphene Citrate Cheaper Without Insurance

Even when employer coverage is unavailable, several pricing strategies can reduce the monthly cost to a manageable figure.

Telehealth Membership Bundles

Several telehealth platforms bundle the physician consultation, prescription, and pharmacy into a flat monthly fee ranging from $49 to $149. The bundled model absorbs the consultation cost, which can otherwise add $150, $250 per visit at a traditional endocrinology practice. HealthRX's own prescribing data (internal, Q4 2025) shows that patients who use a bundled telehealth program spend a median of $89/month all-in for compounded enclomiphene, compared with $175/month when using a separate specialist and retail pharmacy.

Compounding Pharmacy Price Shopping

Compounding pharmacy prices for enclomiphene citrate vary by 40 to 60% across providers for identical formulations. A 30-day supply of 12.5 mg capsules may cost $65 at one 503A pharmacy and $120 at another. Prices are not standardized because compounding pharmacies set their own rates. Calling three to five PCAB-accredited pharmacies and requesting a price quote for a specific dose and quantity is a practical way to identify the lowest cash price in your state.

GoodRx and Coupon Programs

GoodRx and similar discount platforms are primarily designed for FDA-approved drugs with NDCs. Compounded drugs generally do not appear in GoodRx's database because they lack NDCs. However, some telehealth-affiliated compounding pharmacies have negotiated direct pricing with GoodRx or NeedyMeds for their most common compounded formulations. Checking both platforms with the exact compound name and dose is worth the five minutes it takes.

Manufacturer Patient Assistance

No manufacturer patient assistance program exists for compounded enclomiphene because there is no single manufacturer. If the FDA approves a finished enclomiphene product in the future, the manufacturer will likely launch a standard patient assistance program (PAP). Monitoring the FDA's Prescription Drug User Fee Act (PDUFA) action date calendar at fda.gov provides notice of any upcoming approval decisions.

Understanding the Compounding Pharmacy Regulatory Framework

Paying attention to pharmacy accreditation directly affects both safety and, in some benefit scenarios, reimbursement eligibility.

503A vs. 503B Pharmacies

Section 503A pharmacies compound drugs for individual patients based on a valid prescription. Section 503B outsourcing facilities compound larger batches for distribution to healthcare facilities without patient-specific prescriptions. Enclomiphene is typically dispensed through 503A pharmacies. Some employer health plans and ICHRA administrators may ask for proof that the dispensing pharmacy is state-licensed and in good standing. The FDA maintains a list of registered 503B outsourcing facilities at fda.gov, and state boards of pharmacy maintain 503A licensure databases.

PCAB Accreditation

The Pharmacy Compounding Accreditation Board (PCAB) accreditation signals adherence to quality and safety standards above state minimum requirements. Some ICHRA administrators and self-insured employer plans explicitly require PCAB accreditation as a condition of reimbursement for compounded drugs. Confirming accreditation before filling a prescription avoids a rejected reimbursement claim.

Documenting Medical Necessity: What Your Provider Should Include

A prescription alone may not be sufficient for ICHRA reimbursement or an insurance appeal. A clinical note documenting the diagnostic basis for the prescription strengthens every payment pathway.

Minimum Documentation Elements

Your provider's note should include:

• Serum total testosterone level (ideally two morning fasting measurements below 300 ng/dL, as recommended by the Endocrine Society guideline).
• LH and FSH levels confirming secondary (hypothalamic or pituitary) rather than primary hypogonadism.
• Documentation of symptoms: reduced libido, fatigue, or decreased bone density.
• Reason enclomiphene was selected over first-line alternatives, such as fertility preservation intent.
• Monitoring plan, including planned testosterone and LH rechecks at 6 to 12 weeks.

A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that enclomiphene's mechanism of selective estrogen receptor modulation at the hypothalamus produces sustained LH and FSH elevation, driving endogenous testosterone synthesis without suppressing the hypothalamic-pituitary axis the way exogenous testosterone does (Krzastek et al., JCEM 2020). That mechanistic distinction supports the clinical rationale for choosing enclomiphene over TRT in patients where fertility is a concern.

Getting a Diagnosis Code on the Prescription

Prescriptions with an associated ICD-10 diagnosis code (E29.1 for testicular hypofunction, or E23.0 for hypopituitarism if applicable) are more likely to pass ICHRA administrator review and insurance appeals than prescriptions with no diagnostic context. Ask your provider to include the relevant ICD-10 code in both the prescription and the clinical note.

2026 Regulatory Field and What to Watch

The FDA's status on enclomiphene remains unchanged: no approved finished drug product as of the publication date of this article. The agency did issue a draft guidance in late 2023 identifying certain drug substances that raise "major questions of safety or effectiveness" when compounded under Section 503A, but enclomiphene was not on that list as of early 2026. Monitoring the FDA's 503A bulk drug substances list at fda.gov is the most direct way to track any regulatory change that could affect compounding availability.

If FDA approval of a finished enclomiphene product occurs, the coverage picture changes immediately. An FDA-approved drug receives an NDC, enters PBM formulary systems, and becomes eligible for standard prior authorization pathways. That outcome would likely reduce cost for most patients with commercial insurance.

The Endocrine Society updated its position on compounded hormones in 2023, recommending that "compounded bioidentical hormone therapy should not be used unless there is a documented allergy or intolerance to all FDA-approved alternatives," a statement primarily directed at sex hormone therapy in women but reflective of broader institutional caution about compounded preparations (Endocrine Society, 2023). Patients and providers should weigh that context when drafting medical necessity documentation.

Practical Checklist: Steps to Maximize Coverage and Minimize Cost

The following sequence applies to most patients starting enclomiphene in 2026.

1. Get diagnosed properly. Two fasting morning testosterone measurements below 300 ng/dL with documented LH and FSH levels are the foundation of every downstream coverage argument.
2. Request your SPD from HR. Scan it for language about compounded drugs, formulary exclusions, and medical exception processes.
3. Confirm ICHRA or QSEHRA availability. If your employer offers either account, confirm the annual allowance and the administrator's requirements for compounded drug reimbursement.
4. Open or fund an HSA or FSA. If you are on an HDHP, maximize HSA contributions early in the year so funds are available at the pharmacy.
5. Get a prescription with an ICD-10 code. Ask your provider to include the diagnosis code and a brief note documenting why enclomiphene was selected.
6. Call three compounding pharmacies. Get price quotes for your exact dose and quantity from PCAB-accredited 503A pharmacies.
7. Ask about telehealth bundles. If your total cost with a separate specialist and pharmacy exceeds $150/month, compare that to bundled telehealth pricing.
8. File an appeal if denied. Use the Bhasin et al. JCEM 2018 guideline and the Wiehle et al. JCEM 2014 trial data in the letter.